A citation-based method for searching scientific literature


List of co-cited articles
194 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Patton Minkin, Ming Zhao, Zhaoyuan Chen, Jan Ouwerkerk, Hans Gelderblom, Sharyn D Baker. J Chromatogr B Analyt Technol Biomed Life Sci 2008
47
38

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
A Haouala, B Zanolari, B Rochat, M Montemurro, K Zaman, M A Duchosal, H B Ris, S Leyvraz, N Widmer, L A Decosterd. J Chromatogr B Analyt Technol Biomed Life Sci 2009
139
38

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Dirk B Mendel, A Douglas Laird, Xiaohua Xin, Sharianne G Louie, James G Christensen, Guangmin Li, Randall E Schreck, Tinya J Abrams, Theresa J Ngai, Leslie B Lee,[...]. Clin Cancer Res 2003
32

A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
Marie-Christine Etienne-Grimaldi, Nicole Renée, Hassan Izzedine, Gérard Milano. J Chromatogr B Analyt Technol Biomed Life Sci 2009
30
36

Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry.
R Honeywell, K Yarzadah, E Giovannetti, N Losekoot, E F Smit, M Walraven, J S W Lind, C Tibaldi, H M Verheul, G J Peters. J Chromatogr B Analyt Technol Biomed Life Sci 2010
66
32


Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies.
Rajneet K Oberoi, Rajendar K Mittapalli, James Fisher, William F Elmquist. Chromatographia 2013
20
55


Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
Benoit Blanchet, Carole Saboureau, Anne Sophie Benichou, Bertrand Billemont, Fabrice Taieb, Stanislas Ropert, Alain Dauphin, François Goldwasser, Michel Tod. Clin Chim Acta 2009
39
26

Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.
Stéphane Bouchet, Emmanuelle Chauzit, Dominique Ducint, Nadège Castaing, Mireille Canal-Raffin, Nicholas Moore, Karine Titier, Mathieu Molimard. Clin Chim Acta 2011
119
26

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.
Nienke A G Lankheet, Christian U Blank, Henk Mallo, Sandra Adriaansz, Hilde Rosing, Jan H M Schellens, Alwin D R Huitema, Jos H Beijnen. J Anal Toxicol 2011
25
32

A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
Nielka P van Erp, Djoeke de Wit, Henk-Jan Guchelaar, Hans Gelderblom, Trees J Hessing, Jan den Hartigh. J Chromatogr B Analyt Technol Biomed Life Sci 2013
57
23

Molecular basis for sunitinib efficacy and future clinical development.
Sandrine Faivre, George Demetri, William Sargent, Eric Raymond. Nat Rev Drug Discov 2007
516
20


Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma.
Lutz Götze, Axel Hegele, Stephan Klaus Metzelder, Harald Renz, Wolfgang Andreas Nockher. Clin Chim Acta 2012
67
20


Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
Joshua O Haznedar, Shem Patyna, Carlo L Bello, Geoffrey W Peng, William Speed, Xiaoming Yu, Qingling Zhang, Juthamas Sukbuntherng, David J Sweeny, Lida Antonian,[...]. Cancer Chemother Pharmacol 2009
54
17


An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.
L Couchman, M Birch, R Ireland, A Corrigan, S Wickramasinghe, D Josephs, J Spicer, R J Flanagan. Anal Bioanal Chem 2012
53
17

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Vicki L Goodman, Edwin P Rock, Ramzi Dagher, Roshni P Ramchandani, Sophia Abraham, Jogarao V S Gobburu, Brian P Booth, S Leigh Verbois, David E Morse, Cheng Yi Liang,[...]. Clin Cancer Res 2007
365
14


Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
Bill Speed, Hai-Zhi Bu, William F Pool, Geoffrey W Peng, Ellen Y Wu, Shem Patyna, Carlo Bello, Ping Kang. Drug Metab Dispos 2012
71
14

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
Sandrine Faivre, Catherine Delbaldo, Karina Vera, Caroline Robert, Stéphanie Lozahic, Nathalie Lassau, Carlo Bello, Samuel Deprimo, Nicoletta Brega, Giorgio Massimini,[...]. J Clin Oncol 2006
945
14

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Brett E Houk, Carlo L Bello, Bill Poland, Lee S Rosen, George D Demetri, Robert J Motzer. Cancer Chemother Pharmacol 2010
364
14

Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS).
Mukul Minocha, Varun Khurana, Ashim K Mitra. J Chromatogr B Analyt Technol Biomed Life Sci 2012
32
15




Sunitinib maleate.
Michael Atkins, Carole A Jones, Peter Kirkpatrick. Nat Rev Drug Discov 2006
107
11


Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
George D Demetri, Allan T van Oosterom, Christopher R Garrett, Martin E Blackstein, Manisha H Shah, Jaap Verweij, Grant McArthur, Ian R Judson, Michael C Heinrich, Jeffrey A Morgan,[...]. Lancet 2006
11

An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
Yi Zhen, Audrey Thomas-Schoemann, Lilia Sakji, Pascaline Boudou-Rouquette, Nicolas Dupin, Laurent Mortier, Michel Vidal, Francois Goldwasser, Benoit Blanchet. J Chromatogr B Analyt Technol Biomed Life Sci 2013
28
14


Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, M Dror Michaelson, Ronald M Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Negrier, Cezary Szczylik, Sindy T Kim,[...]. N Engl J Med 2007
8

Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Cheryl A Grandinetti, Barry R Goldspiel. Pharmacotherapy 2007
86
8


Sunitinib malate.
Hassane Izzedine, Irina Buhaescu, Olivier Rixe, Gilbert Deray. Cancer Chemother Pharmacol 2007
38
8

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects.
Carlo L Bello, Laurie Sherman, Jihao Zhou, Lev Verkh, John Smeraglia, Janessa Mount, Karen J Klamerus. Anticancer Drugs 2006
113
8

Direct analysis of biological tissue by paper spray mass spectrometry.
He Wang, Nicholas E Manicke, Qian Yang, Lingxing Zheng, Riyi Shi, R Graham Cooks, Zheng Ouyang. Anal Chem 2011
149
8

Sunitinib in patients with metastatic renal cell carcinoma.
Robert J Motzer, Brian I Rini, Ronald M Bukowski, Brendan D Curti, Daniel J George, Gary R Hudes, Bruce G Redman, Kim A Margolin, Jaime R Merchan, George Wilding,[...]. JAMA 2006
951
8


Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.
Milly E de Jonge, Alwin D R Huitema, Jan H M Schellens, Sjoerd Rodenhuis, Jos H Beijnen. Clin Pharmacokinet 2005
80
8


High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid.
Werner J Heinz, Kathrin Kahle, Annegret Helle-Beyersdorf, Diana Schirmer, Ulrike Lenker, Daniela Keller, Peter Langmann, Hartwig Klinker. Cancer Chemother Pharmacol 2011
28
10

HPLC-DAD protein kinase inhibitor analysis in human serum.
Marek Dziadosz, Rüdiger Lessig, Heidemarie Bartels. J Chromatogr B Analyt Technol Biomed Life Sci 2012
23
13



Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study.
Sridhar Veeraraghavan, Satheeshmanikandan Thappali, Srikant Viswanadha, Sandhyarani Chennupati, Santhoshkumar Nalla, Manikantakumar Golla, Swaroopkumar Vakkalanka, Manivannan Rangasamy. J Pharm Biomed Anal 2014
12
25



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.